AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
PDF (2.9 MB)
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Original Article | Open Access

Cancer-educated neutrophils promote lung cancer progression via PARP-1-ALOX5-mediated MMP-9 expression

Lulu Han1,2,3Yuxin Chen1,2,3Nan Huang1Xiaowan Zhou1,4Yanfang Lv1Huizhong Li1,2,3Dafei Chai1,2,3Junnian Zheng2,3( )Gang Wang1,2,3 ( )
Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, China
Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou 221002, China
Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou 221004, China
Department of Oncology, Suzhou Xiangcheng People’s Hospital, Suzhou 215131, China
Show Author Information

Abstract

Objective

Neutrophils are one of the most predominant infiltrating leukocytes in lung cancer tissues and are associated with lung cancer progression. How neutrophils promote lung cancer progression, however, has not been established.

Methods

Kaplan–Meier plotter online analysis and tissue immunohistochemistry were used to determine the relationship between neutrophils and overall survival in lung cancer patients. The effect of neutrophils on lung cancer was determined using the Transwell migration assay, a proliferation assay, and a murine tumor model. Gene knockdown was used to determine poly ADP-ribose polymerase (PARP)-1 function in lung cancer-educated neutrophils. Western blot analysis and gelatin zymography were used to demonstrate the correlation between PARP-1 and matrix metallopeptidase 9 (MMP-9). Immunoprecipitation coupled to mass spectrometry (IP/MS) was used to identify the proteins interacting with PARP-1. Co-immunoprecipitation (Co-IP) was used to confirm that PARP-1 interacts with arachidonate 5-lipooxygenase (ALOX5). Neutrophil PARP-1 blockage by AG14361 rescued neutrophil-promoted lung cancer progression.

Results

An increased number of infiltrating neutrophils was negatively associated with overall survival in lung cancer patients (P < 0.001). Neutrophil activation promoted lung cancer cell invasion, migration, and proliferation in vitro, and murine lung cancer growth in vivo. Mechanistically, PARP-1 was shown to be involved in lung cancer cell-induced neutrophil activation to increase MMP-9 expression through interacting and stabilizing ALOX5 by post-translational protein modification (PARylation). Blocking PARP-1 by gene knockdown or AG14361 significantly decreased ALOX5 expression and MMP-9 production, and eliminated neutrophil-mediated lung cancer cell invasion and in vivo tumor growth.

Conclusion

We identified a novel mechanism by which PARP-1 mediates lung cancer cell-induced neutrophil activation and PARylates ALOX5 to regulate MMP-9 expression, which exacerbates lung cancer progression.

Electronic Supplementary Material

Download File(s)
cbm-21-2-175_ESM.pdf (1.4 MB)

References

1

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71: 209-49.

2

Cao M, Li H, Sun D, He S, Yan X, Yang F, et al. Current cancer burden in china: epidemiology, etiology, and prevention. Cancer Biol Med. 2022; 19: 1121-38.

3

Kargl J, Busch SE, Yang GH, Kim KH, Hanke ML, Metz HE, et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer. Nat Commun. 2017; 8: 14381.

4

Ilie M, Hofman V, Ortholan C, Bonnetaud C, Coelle C, Mouroux J, et al. Predictive clinical outcome of the intratumoral CD66bpositive neutrophil-to-CD8-positive T-cell ratio in patients with resectable nonsmall cell lung cancer. Cancer. 2012; 118: 1726-37.

5

Schernberg A, Mezquita L, Boros A, Botticella A, Caramella C, Besse B, et al. Neutrophilia as prognostic biomarker in locally advanced stage Ⅲ lung cancer. PLoS One. 2018; 13: e0204490.

6

Mandaliya H, Jones M, Oldmeadow C, Nordman Ⅱ. Prognostic biomarkers in stage Ⅳ non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019; 8: 886-94.

7

Shaul ME, Eyal O, Guglietta S, Aloni P, Zlotnik A, Forkosh E, et al. Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. FASEB J. 2020; 34: 4204-18.

8

Russo A, Russano M, Franchina T, Migliorino MR, Aprile G, Mansueto G, et al. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective multicenter study. Adv Ther. 2020; 37: 1145-55.

9

Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022; 22: 173-87.

10

Chen S, Zhang Q, Lu L, Xu C, Li J, Zha J, et al. Heterogeneity of neutrophils in cancer: one size does not fit all. Cancer Biolo Med. 2022; 19: 1629-48.

11

Pylaeva E, Korschunow G, Spyra I, Bordbari S, Siakaeva E, Ozel I, et al. During early stages of cancer, neutrophils initiate anti-tumor immune responses in tumor-draining lymph nodes. Cell Rep. 2022; 40: 111171.

12

Masucci MT, Minopoli M, Carriero MV. Tumor associated neutrophils. Their role in tumorigenesis, metastasis, prognosis and therapy. Front Oncol. 2019; 9: 1146.

13

Xue RD, Zhang QM, Cao Q, Kong RR, Xiang X, Liu HK, et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature. 2022; 612: 141-7.

14

Gong Z, Li Q, Shi J, Li P, Hua L, Shultz LD, et al. Immunosuppressive reprogramming of neutrophils by lung mesenchymal cells promotes breast cancer metastasis. Sci Immunol. 2023; 8: eadd5204.

15

Houghton AM, Rzymkiewicz DM, Ji H, Gregory AD, Egea EE, Metz HE, et al. Neutrophil elastase-mediated degradation of IRS-1 accelerates lung tumor growth. Nat Med. 2010; 16: 219-23.

16

Nywening TM, Belt BA, Cullinan DR, Panni RZ, Han BJ, Sanford DE, et al. Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma. Gut. 2018; 67: 1112-23.

17

Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays. 2004; 26: 882-93.

18

Luscher B, Ahel I, Altmeyer M, Ashworth A, Bai PT, Chang P, et al. ADP-ribosyltransferases, an update on function and nomenclature. FEBS J. 2022; 289: 7399-410.

19

Pazzaglia S, Pioli C. Multifaceted role of PARP-1 in DNA repair and inflammation: pathological and therapeutic implications in cancer and non-cancer diseases. Cells. 2019; 9: 41.

20

Wang G, Huang X, Li Y, Guo K, Ning P, Zhang Y. PARP-1 inhibitor, DPQ, attenuates LPS-induced acute lung injury through inhibiting NF-γb-mediated inflammatory response. PLoS One. 2013; 8: e79757.

21

Dharwal V, Naura AS. PARP-1 inhibition ameliorates elastase induced lung inflammation and emphysema in mice. Biochem Pharmacol. 2018; 150: 24-34.

22

Raftopoulou S, Valadez-Cosmes P, Mihalic ZN, Schicho R, Kargl J. Tumor-mediated neutrophil polarization and therapeutic implications. Int J Mol Sci. 2022; 23: 3218.

23

Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, et al. PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. J Clin Invest. 2019; 129: 1211-28.

24

Wang G, Zhou X, Guo Z, Huang N, Li J, Lv Y, et al. The antifibrosis drug Pirfenidone modifies the immunosuppressive tumor microenvironment and prevents the progression of renal cell carcinoma by inhibiting tumor autocrine TGF-β. Cancer Biol Ther. 2022; 23: 150-62.

25

Wang G, Cao L, Liu X, Sieracki NA, Di A, Wen X, et al. Oxidant sensing by TRPM2 inhibits neutrophil migration and mitigates inflammation. Dev Cell. 2016; 38: 453-62.

26

Chen Y, Han L, Qiu X, Wang M, Chen Z, Cai Y, et al. Reassembling of albumin-bound paclitaxel mitigates myelosuppression and improves its antitumoral efficacy via neutrophil-mediated targeting drug delivery. Drug Deliv. 2022; 29: 728-42.

27

Lanczky A, Gyorffy B. Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation. J Med Internet Res. 2021; 23: e27633.

28

Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2018; 18: 134-47.

29

Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix metalloproteinases in cancer: bringing new life to old ideas. Genes Dis. 2015; 2: 26-34.

30

Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010; 141: 52-67.

31

Vannitamby A, Seow HJ, Anderson G, Vlahos R, Thompson M, Steinfort D, et al. Tumour-associated neutrophils and loss of epithelial PTEN can promote corticosteroid-insensitive MMP-9 expression in the chronically inflamed lung microenvironment. Thorax. 2017; 72: 1140-3.

32

Lee SJ, Kim CE, Yun MR, Seo KW, Park HM, Yun JW, et al. 4-hydroxynonenal enhances MMP-9 production in murine macrophages 5-lipoxygenase-mediated activation of ERK and p38 MAPK. Toxicol Appl Pharm. 2010; 242: 191-8.

33

Kim CE, Lee SJ, Seo KW, Park HM, Yun JW, Bae JU, et al. Acrolein increases 5-lipoxygenase expression in murine macrophages through activation of ERK pathway. Toxicol Appl Pharm. 2010; 245: 76-82.

34

Tu XK, Yang WZ, Shi SS, Chen CM, Wang CH. 5-lipoxygenase inhibitor Zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9. Neurol Res. 2009; 31: 848-52.

35

Kummer NT, Nowicki TS, Azzi JP, Reyes I, Iacob C, Xie S, et al. Arachidonate 5 lipoxygenase expression in papillary thyroid carcinoma promotes invasion via MMP-9 induction. J Cell Biochem. 2012; 113: 1998-2008.

36

Wu F, Wang L, Zhou C. Lung cancer in china: current and prospect. Curr Opin Oncol. 2021; 33: 40-6.

37

Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013; 19: 1423-37.

38

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.

39

Zilionis R, Engblom C, Pfirschke C, Savova V, Zemmour D, Saatcioglu HD, et al. Single-cell transcriptomics of human and mouse lung cancers reveals conserved myeloid populations across individuals and species. Immunity. 2019; 50: 1317-34.e10.

40

Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020; 20: 485-503.

Cancer Biology & Medicine
Pages 175-192
Cite this article:
Han L, Chen Y, Huang N, et al. Cancer-educated neutrophils promote lung cancer progression via PARP-1-ALOX5-mediated MMP-9 expression. Cancer Biology & Medicine, 2024, 21(2): 175-192. https://doi.org/10.20892/j.issn.2095-3941.2023.0248

169

Views

5

Downloads

0

Crossref

3

Web of Science

4

Scopus

Altmetrics

Received: 08 August 2023
Accepted: 06 December 2023
Published: 02 January 2024
©2024 Cancer Biology & Medicine.

Creative Commons Attribution-NonCommercial 4.0 International License

Return